mRNA-3927

Phase 1RNA therapy

Moderna

mRNA-3927 is one of 12 biologic programs targeting Propionic Acidemia. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Propionic AcidemiaActive, not recruiting

AgeActive, not recruiting

Propionic AcidemiaPhase 1/Phase 2

Active, not recruiting

AgePhase 1

Active, not recruiting

Competition

Competitive Landscape

13 competitors in Age

#DrugCompanyPhaseTrials

Actigall

AbbVie

Approved

—2

Rapamune

PPrism Pharmaceuticals

RG6026

Revia

1 5

Pitocin

RRetrophin

Preclinical

1 6

Ambien

PPurdue Pharma LP

Preclinical

—7

Feosol

AAuerbach Hematology Oncology Associates P C

mRNA-3927

2 9

Sodium Nitrite

HHope Pharmaceuticals

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1/2Recruiting

Propionic Acidemia

NCT04159103

Q4 2031

Phase 1/2Recruiting

ART

NCT05130437

Clinical

Trials by Indication[1]

Propionic Acidemia1 trial

Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia

Recruiting· Moderna logo

Moderna·Phase 1/2·NCT04159103·77 enrolled

ART1 trial

A Study to Assess the Long-term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study

Recruiting· Moderna logo

Moderna·Phase 1/2·NCT05130437·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for mRNA-3927. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — mRNA-3927 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for mRNA-3927. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Moderna company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: RNA therapy[2]
Highest Phase: Phase 1[1]
Company: Moderna

mRNA-3927

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q4 2031

Trials by Indication[1]

Propionic Acidemia1 trial

ART1 trial

References

Drug Info

Quick Facts

Related News